WuXi Biologics: Ireland’s largest single-use facility underway

By Flora Southey

- Last updated on GMT

WuXi Biologics' facility in Dundalk, Ireland
WuXi Biologics' facility in Dundalk, Ireland

Related tags Wuxi biologics Ireland Contract manufacturing

The CDMO has broken ground on its first site outside of China – a €325m single-use manufacturing facility in County Louth, Ireland.

Construction has commenced at WuXi Biologics’ Irish facility​, where the contract development and manufacturing organisation (CDMO) will make biologic drugs for commercial production.

The 26-hectare campus will house 48,000L fed-batch and 6,000L perfusion bioreactor capacity, with single-use and continuous bioprocessing capabilities.

Supported by the Republic of Ireland’s Industrial Development Authority (IDA), the €325m ($390m) project is located on the government agency’s greenfield site in Mullagharlin, Dundalk.

According to WuXi Biologics CEO Chris Chen, Ireland’s European Union (EU) membership makes it an attractive option for investment, as the UK prepares to leave the union.

Ireland’s proximity to mainland Europe provides the CDMO “access to [the] EU market,” ​he told us in May of this year.

Global expansion

While the Dundalk facility marks WuXi Biologics’ first outside of China, the firm has plans to build global facilities in Singapore​ and the US​.

The CDMO is also expanding its site network within China. Last month, WuXi Biologics broke ground on a 1.6 million-square-foot Biologics Innovation Center​ in Shanghai, as well as on a $240m manufacturing site​ near Beijing.

Related news

Show more

Related products

show more

Process optimization for mAb commercial manufacturing

Process optimization for mAb commercial manufacturing

Content provided by Catalent | 01-Jun-2023 | Product Presentation

Process characterization and validation is an important step in the product development journey and late-phase development, and it is required before transferring...

Related suppliers